Nirvana Life Sciences Inc.

Recent News

  • Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - November 9, 2022) - Nirvana Life Sciences Inc.(CSE: NIRV) (Nirvana or the "Company") , a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Sheldon Inwentash to the Company's Board of Directors.Mr. Inwentash is founder, chairman and chief executive officer of ThreeD Capital Inc. A veteran entrepreneur, Sheldon has more than 30 years of successful investing experience and an extensive track record of...

    2022-11-09 8:57 AM EST
  • Nirvana Life Sciences Announces Positive Results for Addiction Relapse Prevention from Their Latest Pre-Clinical Psychedelic Drug Study

    Vancouver, British Columbia--(Newsfile Corp. - June 2, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian-based life sciences company focused on developing novel therapeutic products derived from psychedelics to produce non-addictive solutions for opioid addiction treatment and ongoing pain management, in conjunction with Integrative Therapy Discovery (ITD) Labs in Italy, have released comprehensive data on a scientific study that aims in determining the effects that psilocybin has on the heroin-addicted brain. The study...

    2022-06-02 1:00 PM EDT
  • ThreeD Capital Increases Its Investment in Nirvana

    Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) ("Nirvana" or the "Company") is pleased to announce that ThreeD Capital Inc. has increased its investment in Nirvana. The Company announces that it has completed a non-brokered private placement of 500,000 units at a price of $0.30 per unit, for net proceeds of $150,000.00. Each unit consists of one share and one warrant to purchase a share at a price of $0.50 per share with...

    2022-05-31 7:43 PM EDT
  • Nirvana Life Sciences Announces Partner Symeres Can Produce High Volume Controlled Substances

    Vancouver, British Columbia--(Newsfile Corp. - May 24, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a western Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products announces that its strategic partners Symeres are licensed to produce large quantities of controlled compounds required by Nirvana.The company is excited to announce that strategic partner Symeres has confirmed with Nirvana Life Sciences, its ability to produce up to 1000g batches of pharmaceutical Psilocybin...

    2022-05-24 7:32 AM EDT
  • Nirvana Signs Letter of Intent with Innovate Phytotechnologies Inc.

    Vancouver, British Columbia--(Newsfile Corp. - May 17, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products, is pleased to announce that it has signed a letter of intent with Innovate Phytotechnologies Inc. (INVP) for the development and distribution of the Company's psilocybin and psilocin based products. The strategic relationship will begin with the production of 20g each of psilocybin and...

    2022-05-17 9:00 AM EDT
  • Nirvana Life Sciences Inc. Announces the Appointment of Jakson Inwentash to the Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - May 3, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce the appointment of Mr. Jakson Inwentash to the Company's Board of Directors.Mr. Inwentash is a Director and VP Investments at ThreeD Capital, where he focuses on identifying, researching, and meeting with early-stage companies in various disruptive industries as investment targets. He...

    2022-05-03 9:00 AM EDT
  • Nirvana Reports Progress with Health Canada Dealer's License Application and Facility Development

    Vancouver, British Columbia--(Newsfile Corp. - April 26, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) (Nirvana or the "Company"), a Canadian based life sciences company aimed at developing non-addictive chronic pain and relapse preventing products is pleased to announce an update on licensing and development for its Vancouver Lab facility.Mr. Michael McCune, Vice President Operations commented, "We are pleased with the steady progress that our team is making on licensing. The application for the 29 different controlled substances will support...

    2022-04-26 8:49 AM EDT
  • Nirvana Announces First Production of Psilocybin and Psilocin

    Vancouver, British Columbia--(Newsfile Corp. - April 21, 2022) - Nirvana Life Sciences Inc. (CSE: NIRV) ("Nirvana" or the "Company") is pleased to announce that its supply agreement with Symeres B.V. has produced its first 20 grams of Psilocybin and 20 grams of Psilocin. These materials will support the Company's ongoing research and development projects.Dr. Sazzad Hossain, Chief Scientific Officer of Nirvana commented, "We are very pleased to have these materials available as we enter the next phase of research and development.," "Symeres...

    2022-04-21 9:00 AM EDT